C12Y 304/14
Dipeptidyl-peptidases and tripeptidyl-peptidases
Official title: Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
C12Y304/14 (Dipeptidyl-peptidases and tripeptidyl-peptidases) appears on 84 US grants and 183 published applications in this corpus.
Search patents in C12Y- Granted patents
- 84
- Published applications
- 183
- Assignees
- 93
- Inventors
- 370
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 2 |
| 2003 | 2 | 10 |
| 2004 | 3 | 2 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 2 | 1 |
| 2008 | 1 | 8 |
| 2009 | 1 | 5 |
| 2010 | 2 | 1 |
| 2011 | 5 | 6 |
| 2012 | 4 | 5 |
| 2013 | 2 | 5 |
| 2014 | 1 | 6 |
| 2015 | 3 | 11 |
| 2016 | 6 | 10 |
| 2017 | 8 | 16 |
| 2018 | 3 | 10 |
| 2019 | 8 | 14 |
| 2020 | 6 | 9 |
| 2021 | 5 | 9 |
| 2022 | 3 | 12 |
| 2023 | 2 | 14 |
| 2024 | 3 | 15 |
| 2025 | 5 | 4 |
| 2026 | 1 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 304/14005Dipeptidyl-peptidase iv42
- C12Y 304/14009Tripeptidyl-peptidase i24
- C12Y 304/14001Dipeptidyl-peptidase i , i.e. cathepsin-c4
- C12Y 304/1401Tripeptidyl-peptidase ii4
- C12Y 304/14002Dipeptidyl-peptidase ii2
- C12Y 304/14004Dipeptidyl-peptidase iii0
- C12Y 304/14006Dipeptidyl-dipeptidase0
- C12Y 304/14008Tripeptidyl peptidase0
Recent patents
- Targeting peptides for directing adeno-associated viruses (AAVs)16 Jun 2026US 12,653,904 B2California Institute of Technology
- Gene therapy for ceroid lipofuscinoses30 Sep 2025US 12,428,653 B2The Trustees of the University of Pennsylvania
- Multispecific proteins17 Jun 2025US 12,331,090 B2Molecular Partners AG
- Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof22 Apr 2025US 12,281,170 B2StarkAge Therapeutics
- Humanized dipeptidyl-peptidase IV (DPP4) animals25 Mar 2025US 12,256,720 B2Regeneron Pharmaceuticals, Inc.
- Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof13 Aug 2026US 2026/0234284 A1StarkAge Therapeutics
- Novel gene therapy construct for cln2 disease30 Jul 2026US 2026/0216378 A1The Children’s Hospital of Philadelphia
- Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier2 Jul 2026US 2026/0184781 A1JCR Pharmaceuticals Co., Ltd.
- Gene therapy for ceroid lipofuscinoses19 Mar 2026US 2026/0078406 A1The Trustees of the University of Pennsylvania
- Treatment for ovarian cancer with oligonucleotides targeting fibroblast activation protein alpha5 Mar 2026US 2026/0062705 A1
Most cited
By later US patents
- Recombinant AAV capsid protein95US 9,585,971 B2California Institute of Technology · 2017
- Compositions and methods relating to reduction of symptoms of autism63US 6,899,876 B2Prothera, Inc. · 2005
- Compositions and methods relating to reduction of symptoms of autism62US 6,821,514 B2Prothera, Inc. · 2004
- Compositions and methods relating to reduction of symptoms of autism57US 6,808,708 B2Prothera, Inc. · 2004
- Enzyme treatment of foodstuffs for Celiac Sprue47US 7,303,871 B2The Board of Trustees of the Leland Stanford Junior University · 2007